EGFR and non-small cell lung carcinoma: However, the global multicenter, phase III NeoADAURA trial (NCT04351555) demonstrated that osimertinib monotherapy or combination with chemotherapy significantly improved the MPR rate and increased the opportunity for R0 resection in patients with resectable EGFR-mutant NSCLC[27].